Publication:
An increase in erythromycin resistance in methicillin-susceptible Staphylococcus aureus from blood correlates with the use of macrolide/lincosamide/streptogramin antibiotics. EARS-Net Spain (2004–2020)

dc.contributor.authorEl Mammery, Achraf
dc.contributor.authorRamirez de Arellano, Eva
dc.contributor.authorCañada-Garcia, Javier Enrique
dc.contributor.authorCercenado, Emilia
dc.contributor.authorVillar-Gómara, Laura
dc.contributor.authorCasquero-García, Verónica
dc.contributor.authorGarcía-Cobos, Silvia
dc.contributor.authorLepe, José Antonio
dc.contributor.authorRuiz de Gopegui Bordes, Enrique
dc.contributor.authorCalvo-Montes, Jorge
dc.contributor.authorLarrosa Escartín, Nieves
dc.contributor.authorCantón, Rafael
dc.contributor.authorPerez-Vazquez, Maria
dc.contributor.authorAracil, Belen
dc.contributor.authorOteo-Iglesias, Jesus
dc.contributor.authorSpanish EARS-Net Group
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERES (Enfermedades Respiratorias)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.date.accessioned2023-10-10T07:55:53Z
dc.date.available2023-10-10T07:55:53Z
dc.date.issued2023-09
dc.description.abstractObjectives: To describe and analyse erythromycin resistance trends in blood isolates of Staphylococcus aureus (EARS-Net Spain, 2004–2020) and the association of these trends with the consumption of macrolide, lincosamide, and streptogramin B (MLSB) antibiotics. To assess molecular changes that could be involved in erythromycin resistance trends by whole genome analysis of representative isolates. Materials and methods: We collected antibiotic susceptibility data for all firstblood S. aureus isolates in patients from 47 Spanish hospitals according to EARS-Net criteria. MLSB antibiotic consumption was obtained from the Spanish Agency for Medicines and Medical Devices (2008–2020). We sequenced 137 representative isolates for core genome multilocus sequence typing, resistome and virulome analysis. Results: For the 36,612 invasive S. aureus isolates, methicillin resistance decreased from 26.4% in 2004 to 22.4% in 2020. Erythromycin resistance in methicillin-susceptible S. aureus (MSSA) increased from 13.6% in 2004 to 28.9% in 2020 (p < 0.001); however, it decreased from 68.7 to 61.8% (p < 0.0001) in methicillin-resistant S. aureus (MRSA). Total consumption of MLSB antibiotics increased from 2.72 defined daily doses per 1,000 inhabitants per day (DID) in 2014 to 3.24 DID in 2016. By WGS, the macrolide resistance genes detected were erm (59.8%), msrA (46%), and mphC (45.2%). The erm genes were more prevalent in MSSA (44/57, 77.2%) than in MRSA (38/80, 47.5%). Most of the erm genes identified in MSSA after 2013 differed from the predominant ermC gene (17/22, 77.3%), largely because ermT was significantly associated with MSSA after 2013 (11/29, 37.9%). All 13 ermT isolates in this study, except one, belonged to ST398 and came from 10 hospitals and six Spanish provinces. Conclusion: The significant increase in erythromycin resistance in blood MSSA correlated with the consumption of the MLSB antibiotics in Spain. These preliminary data seem support the hypothesis that the human ST398 MSSA clade with ermT-mediated resistance to erythromycin may be involved in this trend.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis research was supported by CIBER—Consorcio Centro de Investigación Biomédica en Red (CB21/13/00095, CB21/13/00006, CB21/13/00054, CB21/13/00068, CB21/13/00084, CB21/13/00099 groups of CIBERINFEC; CB06/06/0058 group of CIBERES), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU. This research was also supported by Personalized and precision medicine grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092), and by the Antibiotic Resistance and Staphylococcus aureus Surveillance Programs of the National Center for Microbiology, Instituto de Salud Carlos III.es_ES
dc.format.page1220286es_ES
dc.format.volume14es_ES
dc.identifier.citationFront. Microbiol. 2023; 14:1220286.es_ES
dc.identifier.doi10.3389/fmicb.2023.1220286es_ES
dc.identifier.e-issn1664-302Xes_ES
dc.identifier.journalFrontiers in Microbiologyes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16546
dc.language.isoenges_ES
dc.publisherFrontiers Media
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PMP22/00092es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fmicb.2023.1220286es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectStaphylococcus aureuses_ES
dc.subjectMacrolideses_ES
dc.subjectST398es_ES
dc.subjectermTes_ES
dc.subjectEARS-Netes_ES
dc.subjectAntibiotic resistancees_ES
dc.subjectAntibiotic consumptiones_ES
dc.titleAn increase in erythromycin resistance in methicillin-susceptible Staphylococcus aureus from blood correlates with the use of macrolide/lincosamide/streptogramin antibiotics. EARS-Net Spain (2004–2020)es_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication34d7101f-ebe8-4d14-a0e0-a11b18c02d05
relation.isAuthorOfPublication566a7944-6385-4372-93b6-1a280e855a91
relation.isAuthorOfPublication514ea39a-76d7-423b-9103-0b523713f906
relation.isAuthorOfPublicationa7e0896d-588c-46f0-aead-9eacac1f3c34
relation.isAuthorOfPublication14181d60-ca43-42c6-8248-f96405b4ae2a
relation.isAuthorOfPublicationbcfa655d-9814-4372-a0a8-43b192fc26d0
relation.isAuthorOfPublication0ee7fb0c-569f-4530-9b12-8f87b4e6dd53
relation.isAuthorOfPublication4ac67376-8b3e-48bd-9415-8770421fdd67
relation.isAuthorOfPublication.latestForDiscovery34d7101f-ebe8-4d14-a0e0-a11b18c02d05
relation.isFunderOfPublication0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72
relation.isFunderOfPublication14455813-7c16-4672-affe-a407a07d9f72
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication.latestForDiscovery0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72
relation.isPublisherOfPublication9f9fa5ea-093b-43d8-bf2c-5bd65d08a802
relation.isPublisherOfPublication.latestForDiscovery9f9fa5ea-093b-43d8-bf2c-5bd65d08a802

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
IncreaseErythromycinResistance_2023.pdf
Size:
1.49 MB
Format:
Adobe Portable Document Format
Description:
Articulo
Loading...
Thumbnail Image
Name:
Table1_IncreaseErythromycinResistance_2023.xlsx
Size:
36.71 KB
Format:
Microsoft Excel XML
Description:
supplementary material